Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology

NEXT STORY
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
PREV STORY
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

author_avatar
NASDAQ Market News

WellNow Allergy Launches to Bring Convenience and Flexibility to Allergy Testing and Immunotherapy

author_avatar
NASDAQ Market News

Editas Medicine Grows Scientific Leadership with Two New Appointments

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a ...

author_avatar
NASDAQ Market News